Try our corporate solution for free!
+1 (212) 419-5770

Drug cost distribution by drug type in public drug plans Canada 2017/2018

Patented drugs had a share of nearly 63 percent of drug costs in select public Canadian drug plans. This statistic depicts the distribution of drug costs by drug type in select Canadian public drug plans in Canada as of fiscal year 2017/2018.

Distribution of drug costs by drug type in select public Canadian drug plans in 2017/2018

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in

Release date




Survey time period

fiscal year 2017/2018

Supplementary notes

This analysis only includes data for beneficiaries that met their deductible and received public reimbursement. Direct-acting antiviral (DAA) drugs are used in the treatment of hepatitis C. High-cost drugs have an average annual treatment cost of greater than $10,000 and include both biologics and non-biologics.
Included are: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and Labrador, and the Non-Insured Health Benefits Program.
* The patented medicines market segment includes all medicines that had patent protect at some time during in the period of study, even if the patent expired during that period. As such, the 2017/18 growth does not reflect the loss of patent exclusivity for some top-selling medicines over the course of the fiscal year.
** This market segment includes devices, compounded drugs, and other products that are reimbursed by public drug plans but do not have a Health Canada assigned Drug Identification Number (DIN).

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Further Content: You might find this interesting as well

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.